Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
Monday, September 28, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Zenkuda (tarcocimab tedromer) successfully met its primary endpoint in the pivotal DAYBREAK trial for wet age-related macular degeneration (wAMD), showing significant vision improvements and rapid retinal drying. Notably, 54% of patients were able to maintain a 6-month dosing interval. This positions Zenkuda as a potential first-line treatment option.
Market Sentiment Analysis
POSITIVE FACTORS
Zenkuda met primary endpoints with significant vision gains.
Majority of patients achieved sustained retinal drying.
Establishes a new standard-of-care in wAMD treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
7.9%
average across 11 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
Tarcocimab tedromer
Phase 3 · Wet Age-related Macular Degeneration
Full Press Release Details
Zenkuda (tarcocimab tedromer) met the primary endpoint (p-value of 0.0007) demonstrating meaningful vision gains as well as rapid and sustained retinal drying with the majority of patients (54%) on 6-month dosing, establishing a first-line benchmark in wet age-related macular degeneration (wAMD)
Frequently Asked Questions
What is Zenkuda?
Zenkuda, or tarcocimab tedromer, is a treatment for wet age-related macular degeneration.
What were the results of the DAYBREAK trial?
The DAYBREAK trial showed Zenkuda met primary endpoints with significant vision gains.
How many patients were on a 6-month dosing interval?
54% of patients in the trial maintained a 6-month dosing interval.
What does 'treat-to-dryness' mean?
Treat-to-dryness refers to a strategy aimed at achieving complete retinal drying in patients.